Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Purine nucleoside phosphorylase (PfPNP) from Plasmodium falciparum is an essential enzyme in the parasite’s purine salvage pathway. P. falciparum is a purine auxotroph and relies entirely on salvaging purines from its host for nucleic acid synthesis. PfPNP catalyzes the reversible phosphorolysis of N-glycosidic bonds in 6-oxopurine (deoxy)ribonucleosides to produce hypoxanthine and ribose 1-phosphate. Hypoxanthine is an essential precursor for all purines required for DNA/RNA synthesis in P. falciparum. Transition state analog inhibitors such as DADMe-Immucillin-G potently inhibit both human and malarial PNPs and can clear infections in animal models by inducing lethal purine starvation in parasites. Resistance can arise via gene amplification or point mutations affecting inhibitor binding but often at significant cost to catalytic efficiency.
Transition state analog inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Purine nucleoside phosphorylase (Plasmodium falciparum) (PfPNP).